Taken together, these results suggest that LRH‐1/NR5A2 agonistic activation triggers mitohormesis in T1D M1, that contributes to a pro‐inflammatory immune‐paralysed state with simultaneous inhibition of the inflammasome, blunting further activation of cytokines. Here, NR5A2 is linked to type 1 diabetes mellitus.